Business Wire

Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes

Share

The first data from Europe, Israel and East Asia in the EMPRISE real-world evidence study have been presented, revealing a risk reduction in cardiovascular outcomes associated with empagliflozin compared to DPP-4 inhibitors. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced the study results today, which included over 130,000 adults with type 2 diabetes, with or without cardiovascular disease, showing a:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210628005266/en/

  • 45 percent relative risk reduction (RRR) in all-cause mortality;
  • 29 percent RRR in hospitalization for heart failure;
  • 33 percent RRR in a composite endpoint including heart attack, stroke and all-cause mortality.1

These results were consistent in people with or without cardiovascular disease. The European, Israeli and East Asian results were presented at the 81st American Diabetes Association (ADA) Scientific Sessions, with further European analyses to be revealed at the European Society of Cardiology (ESC) Heart Failure Congress in June–July 2021, and the ESC Congress in August 2021.

The EMPRISE findings confirmed empagliflozin’s well-established safety profile. Empagliflozin was not associated with a risk of acute kidney injury - analyses showed a 51 percent RRR in acute kidney injury requiring dialysis. There was a similar risk of lower limb amputation and bone fractures as with DPP-4 inhibitors. In addition, there was an increased risk of diabetic ketoacidosis, which is consistent with empagliflozin’s known safety information.1

“The risk of hospitalization for heart failure is up to five times higher if you have type 2 diabetes. Heart failure has a considerable impact on a person’s quality of life and prognosis, plus associated healthcare costs,” commented EMPRISE EU investigator Professor Avraham Karasik, Professor and Vice Dean, Sackler School of Medicine, Tel-Aviv University. “These latest EMPRISE findings demonstrate the impact of empagliflozin in the real-world across Europe, Israel and East Asia, supporting its role in reducing cardiovascular complications in people with type 2 diabetes.”

Type 2 diabetes significantly increases the risk of cardiovascular morbidity and mortality. One in two people with type 2 diabetes die from a cardiovascular event globally, and US data show that those with diabetes are twice as likely to develop heart failure than those without.2,3

“The EMPRISE study evaluates extensive endpoints in a broad patient population, providing valuable insights into empagliflozin’s cardiovascular risk reduction potential in the treatment of type 2 diabetes,” said Waheed Jamal, MD, Corporate Vice President and Head of Cardiometabolic Medicine, Boehringer Ingelheim. “These results are positive and encouraging for patients, who will benefit from our continued focus on improving the outcomes for people with cardio-renal-metabolic diseases, like type 2 diabetes and heart failure.”

Findings from the EMPRISE real-world evidence study complement insights from the EMPA-REG OUTCOME® trial, which showed that empagliflozin provides cardiovascular and renal benefits, in addition to metabolic effects, in people with type 2 diabetes and established cardiovascular disease. The EMPA-REG OUTCOME® trial found that empagliflozin reduced the relative risk of hospitalization for heart failure by 35 percent, all-cause mortality by 32 percent and incident or worsening kidney disease by 39 percent, compared to placebo.4

“The evidence seen in the EMPRISE analysis provides reassurance supporting empagliflozin’s safety profile,” added Leonard Glass, Vice President of Medical Affairs, Lilly. “It is five years since the landmark EMPA-REG OUTCOME study and these latest EMPRISE findings add to the wealth of robust, real-world data demonstrating empagliflozin’s effectiveness and safety in routine clinical practice worldwide.”

+++

About EMPRISE

The EMPRISE real-world evidence study involves nearly 382,000 people with type 2 diabetes from 12 countries providing a comprehensive clinical picture of empagliflozin in treating people with type 2 diabetes compared to DPP-4 inhibitors or GLP-1 receptor agonists (two active comparators). EMPRISE aims to assess the comparative effectiveness, safety, healthcare resource utilization and costs of care, and includes the US, Europe, Israel and East Asia.1,5

About Cardio-Renal-Metabolic Conditions

Boehringer Ingelheim and Lilly are driven to transform care for people with cardio-renal-metabolic conditions, a group of interconnected disorders that affect more than one billion people worldwide and are a leading cause of death.6

The cardiovascular, renal and metabolic systems are interconnected, and share many of the same risk factors and pathological pathways along the disease continuum. Dysfunction in one system may accelerate the onset of others, resulting in progression of interconnected diseases such as type 2 diabetes, cardiovascular disease, heart failure, and kidney disease, which in turn leads to an increased risk of cardiovascular death. Conversely, improving the health of one system can lead to positive effects throughout the others.7,8

Through our research and treatments, our goal is to support people’s health, restoring the balance between the interconnected cardio-renal-metabolic systems and reducing their risk of serious complications. As part of our commitment to those whose health is jeopardized by cardio-renal-metabolic conditions, we will continue embracing a multidisciplinary approach towards care and focusing our resources on filling treatment gaps.

About Heart Failure

Heart failure is a progressive, debilitating and potentially fatal condition that occurs when the heart cannot supply adequate circulation to meet the body’s demands for oxygenated blood, or to do so requires increased blood volume leading to fluid accumulation (congestion) in the lungs and peripheral tissues. 9 It is a widespread condition affecting over 60 million people worldwide and expected to increase as the population ages. Heart failure is highly prevalent in people with diabetes;10 however, approximately half of all people with heart failure do not have diabetes.11

About Empagliflozin

Empagliflozin (marketed as Jardiance®) is an oral, once-daily, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk reduction data in its label in several countries.12,13,14

Please click on the following link for ‘Notes to Editors’ and ‘References’ http://www.boehringer-ingelheim.com/press-release/real-world-benefit-shown-t2d-treatment

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Fabian Agel
Product Communication Manager
Boehringer Ingelheim
Email: press@boehringer-ingelheim.com
Phone: +49 (6132) 77 173136

Greg Kueterman
Senior Director of Communications
Eli Lilly and Company
Email: kueterman_gregory_andrew@lilly.com
Phone: +1-317-432-5195

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Conviva and the Trade Desk Partner to Improve Contextual Advertising for Premium Streaming Publishers29.7.2021 19:04:00 CEST | Press release

Conviva, the intelligence cloud for streaming media, and global advertising technology leader The Trade Desk, have entered a first-of-its-kind partnership to provide the streaming advertising industry the contextual content signals needed in the bidstream to improve their connected TV campaigns based on signals and effectiveness. Together, the two companies will help premium publishers supply programmatic buyers with the network, genre, rating, length and other detailed data sorely lacking in the streaming industry while still maintaining data control. Details of the partnership, product offering, participating publishers and how premium publishers can participate and benefit, will be available via a webinar in August. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005953/en/ The Trade Desk + Conviva (Graphic: Business Wire) According to Conviva’s State of Streaming Advertising report, released in June 2021, only 39% o

New Harris Poll: Cybersecurity Fears May Stall COVID-19 Digital Vaccine Card Adoption in the United Kingdom, Identity Theft and Fake Cards Top List of Concerns29.7.2021 17:02:00 CEST | Press release

Anomali, the leader in intelligence-driven cybersecurity solutions, today announced availability of its latest survey conducted by The Harris Poll. The study, which gathered responses from more than 1,000 adults aged 18 and over in the United Kingdom, reveals that more than three-quarters of British adults have cybersecurity fears around the use of COVID-19 digital vaccination cards. Additional findings showed which entities respondents believe are responsible for protecting them against cyberattacks and who they believe the most likely culprits will be. A majority of respondents predict that a disruptive cyberattack will follow digital vaccine card adoption, findings also reveal confidence levels when it comes to how prepared the nation is to mount a defense. Among key findings: 76% have cybersecurity concerns related to COVID-19 digital vaccination cards. Identity theft topped the list at 51%, with fake vaccine cards that could be used to hack smartphones (44%) and data breaches (45%

QuadraGen Announces the Launch of Its Next Generation Commercial Loan Processing SaaS Platform and Edward Ho Joins As Chairman29.7.2021 16:00:00 CEST | Press release

QuadraGen announces the launch of its next generation commercial loan servicing SaaS platform to help financial institutions transform their complex loan processing capabilities. The QuadraGen Platform supports various areas of loan operations, enabling more efficient and effective processing of loan information, risk management, and decision-making. The QuadraGen SaaS platform consists of a suite of independently deployable microservices that augment existing technology, filling in gaps where processes and functions are not well executed, or replacing legacy capabilities with its next generation software. QuadraGen’s key differentiator is its team of experts, who have decades of commercial lending experience understanding and solving complex loan operation issues. Financial institutions are challenged by the size, complexity, number of participants, and speed of the loan markets. Many institutions use in-house or legacy systems that are inadequate for today’s ever-growing needs. Quadr

Comcast Announces Peacock Coming to Sky29.7.2021 15:30:00 CEST | Press release

Comcast today announced NBCUniversal and Sky will make Peacock available at no additional cost to nearly 20 million Sky customers in Europe. Beginning later this year, Peacock will make its international debut across Sky platforms, including Sky Q, NOW, and Sky Ticket, currently serving customers throughout the UK, Ireland, Germany, Italy, Austria, and Switzerland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005660/en/ “Comcast’s Xfinity has been integral to the success of our go-to-market strategy with Peacock in the U.S., and we see a similar opportunity to expand internationally with Sky,” said Jeff Shell, Chief Executive Officer, NBCUniversal. “We are excited to bring Peacock to millions of Sky customers and add incredible value to their platforms with a premium catalog of the best entertainment from across NBCUniversal that is included with their subscription. By leveraging Comcast’s Xfinity platforms in the U.

BOW Group Acquires Musart, Adding Innovative Art Marketplace to Its Offering29.7.2021 15:15:00 CEST | Press release

BOW Group today announced that it has successfully completed the acquisition of Musart.com, a fast-growing online destination to buy original artworks and licensed products. This transaction will allow BOW Group to seize new opportunities in the booming digital art market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005637/en/ (Photo: Musart) “BOW Group and Musart share the same passion for good yet accessible design that brings emotions to consumers at every moment of the day,” said Boris Brault, BOW Group Founder and CEO. “Together, with Musart’s unique product curation and established relationships with leading institutions, we can conquer the thriving online art market thanks to our global ecommerce, logistics and development capabilities. With Musart in our portfolio, we are expanding our offering and enhancing the growth potential of our business beyond IoT and lifestyle objects. Today, the art world is fundam

IWBI Collaborates with Leading Organizations to Launch WELL Enterprise Provider Designation29.7.2021 15:00:00 CEST | Press release

The International WELL Building Institute (IWBI) today launched the WELL Enterprise Provider (WELL EP) designation for organizations that demonstrate expertise for delivering a comprehensive suite of WELL solutions at a portfolio or enterprise scale. WELL EPs guide their clients to identify and implement WELL strategies, helping companies meet their larger business objectives in areas such as environmental, social and governance (ESG) reporting, human and social capital management, and workplace strategy and policy. Through this new program, IWBI and WELL EPs work together to more efficiently deliver the many benefits of WELL solutions across real estate portfolios and entire organizations. Companies granted the WELL EP designation offer their demonstrated expertise in WELL along with tailored resources to support the growing demand for enhanced health and well-being for employees, customers and communities. “In the wake of the COVID -19 pandemic, the exponential growth of WELL adoptio

MapleStory M Third Anniversary Culminates in Massive Update With New Angelic Buster Character and In-Game Celebration Events29.7.2021 15:00:00 CEST | Press release

MapleStory M, the free-to-play mobile MMORPG for iOS and Android, is continuing its third anniversary celebration with the introduction of Angelic Buster and a host of events for players to enjoy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005175/en/ MapleStory M Third Anniversary Culminates in Massive Update With New Angelic Buster Character and In-Game Celebration Events (Photo: Business Wire) Born as a disgraced Nova without a tail or magic, Angelic Buster inherited the powers of Eskalade, an ancient dragon residing inside an ancient relic of Pantheon. Equipped with a dragon shaped arm cannon, known as Soul Shooter, Angelic Buster is able to blast waves of enemies with ease. In her second slot, this Nova Pirate holds on to the power of Eskalade in a special ring, known as Soul Ring, transforming her into Angelic Buster and allowing her to use her special skills. New characters between levels 3 and 120 can level